KJB participated in a clinical trial sponsored by Emalex Biosciences and was an unpaid consultant for Noema Pharma AG; he received research support from Zhittya Genesis Medicine and from NIH (R01MH118217, UL1TR002345, R01MH126213, R21NS133875). 

Grant information

Supported in part by EMTICS (Grant No. 278367), TS-EUROTRAIN (Grant No. 316978), EU (FP7-HEALTH-2011 No. 278367, FP7-PEOPLE-2012-ITN No. 316978), DFG: GZ MU 1527/3-1 and GZ MU 1527/3-2, BMBF: 01KG1421, Tourette Gesellschaft Deutschland e.V., Else-Kröner-Fresenius-Stiftung, the National Institutes of Health (Grant Nos. R01NS105746, R01MH118217, UL1TR002345, R01MH126213, R21NS133875, R01MH127187, R21NS133875), and the U.S. National Science Foundation (Grant Nos. 2006929 and 1715202). The authors confirm that the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.